05 Mar
Press Release

Scilex Holding Company Sets Launch Price of $595 per 150ml bottle of Gloperba®, its First and Only Liquid Oral Version of the Anti-Gout Medicine Colchicine Indicated for the Prophylaxis of Painful Gout Flares in Adults; Expected Plans to Launch in the First Half of 2024

Gloperba® is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. Gout is a painful arthritic disorder affecting an estimated...

Read more

02 Mar
Press Release

Scilex Holding Company Announces that the Official Committee of Unsecured Creditors of Sorrento Therapeutics, Inc., has Filed a Motion with the U.S. Bankruptcy Court to Extend the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend from March 31, 2024 to September 30, 2024

PALO ALTO, Calif., March 02, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain,...

Read more

scilex-no-pic
Read More
01 Mar
Leadership

Gigi DeGuzman

Gigi DeGuzman is a seasoned professional with over 25 years of experience in human resources, operations management, facilities management, event planning, executive coordination, and administrative operations. She has played a significant role over...

Read more

scilex-no-pic
Read More
01 Mar
Leadership

Mike Ciaffi

Mike has over 25 years in the pharmaceutical industry.  Mike currently serves as the National Sales Director at Scilex Holding Company. Mike joined Scilex in 2018 as a Regional Business Director to...

Read more

27 Feb
Press Release

Scilex Holding Company Announces Acceptance of Abstract for Poster and Oral Presentation at the Annual Meeting of the American Academy of Pain Medicine (AAPM)

PALO ALTO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and...

Read more

26 Feb
Press Release

Scilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Enters into a Term Sheet with Virpax Pharmaceuticals, Inc. Regarding a Mutual Release and Settlement Agreement

PALO ALTO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and...

Read more

12